Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
Following the recent playbook, CinCor raises $225M on back of positive PhII readout
On Monday, CinCor Pharma drummed up positive Phase II data for its hypertension drug baxdrostat, following it later that day with a public offering …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
